ceo seri back deal model
confid back half improv sustain
notabl bard deal temper perform
convict underli deal model suggest earn
acceler better path ahead
ceo seri vinc forlenza bd ceo seri weekli call
ceo across medic devic field discuss key structur dynam
invest debat recent host vinc forlenza chairman ceo
bd bd under-perform broader index follow bard deal
one-tim dynam obscur underli health busi walk
away call increas convict sustain deal
model becom clear come quarter
tale two deal bd outperform broader equip
suppli index pt vinc forlenza tenur exhibit closer look
show perform split around two larg deal exhibit
defin bd recent transform carefus announc octob
bard announc april acquisit share outperform
follow carefus given acquisit dramat accret
higher return better financ key franchis acceler
howev perform sinc bard deal challeng given
higher leverag one-tim dynam hurrican ep
headwind obscur progress manag remain convinc
outlook deal model delv
confid near-term financi outlook investor concern
quarterli volatil manag see recent volatil
idiosyncrat given headwind time dynam expect consist
improv manag remain confid top-line
acceler highlight life scienc acceler move past
anniversari flu kiestra bd max intervent strong product
pipelin includ wavelinq venovo covera lesser extent dcb/btk
one concern oper margin expect
improv bp h/h wider seen histor bp
confid express back half improv driven fx
growth/mix continu cost synergi sens earn
could prove conserv manag held firm balanc
headwinds/tailwind remain tariffs/resin improv
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
off-set fx worsen
earli read look encourag provid guidanc
specif manag remain confid deal model
impli top-line growth mid-teen underli ep growth sever
headwind flu resin divestitur impact tax tailwind abat
see key factor ep growth loss gore royalti
debt paydown fx manag remain confid lower interest
expens less divestitur flu impact mostli off-set gore royalti
headwind suggest street estim growth
achiev conserv model ep growth line
deal model fx remain swing factor
medic manag solut get go success
carefus come mani factor strateg vision
strategi defin deal investor initi fear carefus would
wamgr dilut growth acceler compani take
pump share sinc deal includ pt last year estim
pyxi system convert pyxi es key debat investor
whether continu manag think given multipl
underappreci driver includ healthsight famili product
rowa system medic manag retail pharmaci see doubl
digit growth europ outpati movement manag
vocal busi enter differ era push less acut
set sustain growth upper end mid-singl digit
busi appreci street
intervent acceler come bard grew exclud
hurrican bd intervent effect bard exclud picc
grown last quarter surgic seen headwind hurricane-
driven share loss manag expect recoup progel
recal back market addit headwind revers
manag expect phasix benefit broader robot push
hernia discuss relationship phasix robot
debat seri last year peripher acceler come btk approv late
driver wavelinq tva medic along sever product
driver manag expect segment grow doubl digit
broadli integr bard sale market team complet
manag remain confid intervent segment acceler
growth
next bd lifesci bd gener look promot senior
posit within compani brought patrick kaltenbach
agil last april head life scienc divis sens signal
chang strateg direct activ bd bioscienc unit domin flow
franchis make life scienc covet busi unit long felt
could stand alon spin revers morri trust number
tool suitor discuss strategi manag number
occas includ confer last year avail vinc forlenza
commentari reaffirm compani keep bd intact suggest strateg
activ divis come within addit
product strateg perspect manag excit
immunolog next gener flow
need anoth larg deal given carefus bard deal
fear bd move toward roll-up strategi could impair multipl
manag look ad complex compani
rather look simplifi busi build custom centric
start debt paid significantli bd could look
increas capit return sharehold dividend increas buyback
manag express interest tuck-in transform
note size remain flexibl perhap importantli given compani
transform last year manag believ larg deal
necessari addit vinc year bd halfway
year ceo given promot last year tom polen
presid see possibl transit next month
would chang guard tom intim involv
carefus bard compani decad
convers suggest earn intern support role
expect clariti deal model emerg bd perform
weigh idiosyncrat item season obscur
healthi underli deal model headwind season die
later year think lead greater
appreci deal model bottom line acceler
morgan stanley research thomson reuter reflect total return includ reinvest dividend
exhibit bd perform tale deal
cfn
perform
morgan stanley research thomson reuter reflect total return includ reinvest dividend use date deal announc
benchmark date
price target base multipl base case
ebitda premium peer organ growth improv becom evid
new product ramp cost program gain traction bard synergi
integr track bd/bard deal model drive mid-teen underli ep
risk price target includ integr fall behind schedul promis
synergi fail materi ii macro trend get wors competit pressur em
mount iii new product launch fail live expect
